Resveratrol for Exudative Age-Related Macular Degeneration

Influence of Resveratrol and Resvega Versus Placebo on Incidence of Bilateralisation of Exudative AMD: a Double Masked Prospective Study.

This is an interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration.

Interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration.

Comparison of incidence of choroidal neaovascularization between each study group will be performed.

Inclusion Criteria:

• Men or women aged 55 or more with unilateral exudative AMD
• Visual acuity less or equal to 20/25 in the most affected eye

Exclusion Criteria:

• Allergy to an investigational product
• atrophic Age-Related Macular Degeneration or age related maculopathy
• significant media opacities
• Other retinal pathology (diabetic retinopathy, high myopia, retinal dystrophy)
• Recent Cataract surgery
• Previous history of vitrectomy
• Acute or chronic severe organ failure
• Present participation in other clinical research study